On 20 July 2023, Sosei Group Corporation, which oversees GJE client and leading fully integrated biopharmaceutical company Heptares Therapeutics Limited, completed its acquisition of Idorsia’s pharmaceuticals business in Japan and APAC (ex-China).
A GJE team headed by Ian Jones, with associates Ash Earl and Charlie O’Neill, provided IP support in the acquisition of Idorsia by Sosei Group Corporation as part of the due diligence for Pivlaz® (clazosentan) and daridorexant – drugs used to treat cerebral vasospasm and insomnia respectively.
To see how GJE supports in-house IP teams, please click here or contact Ian, Ash or Charlie who would be delighted to hear from you.
Related resources
Does T 116/18 Tip the Balance in Favour of Patentees in the Post-Published Evidence Debate at the EPO?
The Enlarged Board of Appeal in G 2/21 established new requirements for determining when post‑published evidence can be...
G 1/22 and G 2/22: EPO Publishes Decision on Priority Entitlement
The EPO have published the eagerly anticipated G1/22 and G2/22 decision of the Enlarged Board of Appeal, providing...
Patent Law & Practice at a Glance
We regularly review changes to patent law and practice at the UKIPO, EPO and in other jurisdictions so...
T 873/21 – A Stable Decision or More Plausibility Fences to Jump?
The Enlarged Board of Appeal in G 2/21 established new guidance for determining when post‑published evidence can be...
Patent Law & Practice at a Glance
We regularly review changes to patent law and practice at the UKIPO, EPO and in other jurisdictions so...
SPCs for ‘Add-On’ Combination Therapies: Problems with Unaligned Product Definitions
The UK High Court has issued a judgment in Newron Pharmaceuticals SPA v UKIPO,[1] upholding the decision not...